Ipsen: presents results of study in FOP
(CercleFinance.com) - Ipsen announces the results of the MOVE trial, the first and only multi-centre Phase III study in fibrodysplasia ossificans progressiva (FOP), or Stone Man Syndrome which will be announced at the ASBMR annual meeting on 12 September.
"Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene," Ipsen said.
Results from the third interim analysis of the MOVE trial, with 107 participants, suggest that "palovarotene may be an important therapeutic option in FOP," Ipsen said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene," Ipsen said.
Results from the third interim analysis of the MOVE trial, with 107 participants, suggest that "palovarotene may be an important therapeutic option in FOP," Ipsen said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.